Bispecifics Network

Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.

Philadelphia Experts Share How Bispecific Delivery in Myeloma Varies by Site

In an AJMC stakeholder interchange, moderator Sandra Susanibar-Adaniya, MD, MS, of Penn Medicine, led academic and community clinicians through the operational, safety, and reimbursement challenges of moving teclistamab-and talquetamab-based regimens into earlier lines of relapsed/refractory multiple myeloma and into outpatient, community-based care.

91% of Community Oncology Sites Offer Bispecifics Despite Barriers

Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.

Building Community Infrastructure for Bispecifics and CAR T

For Bhavana Bhatnagar, DO, delivering bispecifics and CAR T-cell therapy requires infrastructure, education, SOPs, and experienced academic colleagues.

Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.

Expanding Access to CAR T-Cell Therapy, Bispecific Antibodies: Swarup Kumar, MD

Swarup Kumar, MD, emphasizes that preparation is central to positive outcomes and includes patient education and early intervention when needed.

Advance Planning Eases Bispecific Therapy Burden for Patients

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Before the First Bispecific Dose, Community Practices Need a Playbook

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

Infrastructure, Payment Gaps Persist for Bispecifics in the Community

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Bispecifics in the Community: Infrastructure, Education, the Future

Community Bispecifics Success Hinges on Education, Reimbursement

Community oncology can navigate bispecific therapy rollout with staff training, clear handoffs, and reliable reimbursement, said Lekan Ajayi, PharmD.

Bispecifics' Step-Up Dosing Puts Pressure on Community Resources

Community oncology grapples with the logistics of bispecifics with step-up dosing straining staff and reimbursement, said Lekan Ajayi, PharmD.